SecBot SecBot
Biotech Drug Report Generated Nov 13, 2026

CARDAMYST

MIST·Milestone Pharmaceuticals Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially launched in the US (FDA approval December 2025, launch began February 2026). Also approved in China (September 2026).
Why 4/10
CARDAMYST is already FDA-approved and commercially launched, so there is no pending PDUFA or pivotal readout for the PSVT indication. The next hard catalyst is the Phase 3 ReVeRA-301 topline readout for AFib-RVR, but no specific date has been announced. As an approved drug with no imminent binary catalyst, the impact score is capped at 5.
Actionable Insight NEUTRAL

CARDAMYST is already approved and launched, so the next major catalyst is the Phase 3 ReVeRA-301 topline readout for AFib-RVR, which could expand the addressable market significantly. The company's Q3 2026 earnings today showed accelerating prescription growth (73% sequential revenue increase) but also a 30% cost-cutting plan, and the stock fell ~20% on the day. Watch for quarterly prescription and revenue trends as the key near-term value drivers.

Price Chart

Loading chart...

Executive Summary

CARDAMYST (etripamil) is a self-administered nasal spray approved by the FDA in December 2025 for paroxysmal supraventricular tachycardia (PSVT), a condition causing sudden episodes of rapid heart rate. It is the first at-home treatment option for PSVT in 30 years, offering an alternative to emergency room visits for intravenous drugs. Milestone Pharmaceuticals (MIST, Nasdaq) launched the drug commercially in early 2026. Q3 2026 results reported today showed 73% sequential revenue growth but the company is cutting costs by 30% to extend its cash runway. The stock has fallen from ~$3 pre-approval to $0.52, reflecting investor skepticism about commercial uptake against cheap generic alternatives. A Phase 3 trial for a second indication (AFib-RVR) is underway, and China approval was granted in September 2026.

How It Works

CARDAMYST (etripamil) is a rapid-acting L-type calcium channel blocker delivered as a nasal spray. It works by slowing the electrical signals in the heart that cause sudden episodes of rapid heart rate (paroxysmal supraventricular tachycardia, or PSVT). Patients self-administer the spray into each nostril at the onset of symptoms to convert the abnormal heart rhythm back to normal. It is the first FDA-approved drug that patients can use at home for this condition, rather than having to go to an emergency room for intravenous treatment.

Trial Status

CARDAMYST was FDA-approved in December 2025 based on Phase 3 clinical trials for PSVT. A Phase 4 registry (RESET-PSVT) is collecting real-world data. A separate Phase 3 registrational trial (ReVeRA-301) for atrial fibrillation with rapid ventricular rate (AFib-RVR) began enrolling in August 2026.

The Two-Sided Case

▲ Bull Case4
CARDAMYST is the first FDA-approved self-administered treatment for PSVT in 30 years, offering patients an at-home option that could reduce costly emergency room visits. The MedPage Today article from December 2025 notes it is a 'rapid-acting L-type calcium channel blocker' for at-home tachycardia conversion.
Q3 2026 results showed accelerating commercial traction: CARDAMYST revenue rose 73% sequentially, with steady prescription growth and new prescriber expansion, per the company's November 13, 2026 earnings release.
The company is pursuing a second, larger indication: a Phase 3 registrational trial (ReVeRA-301) for atrial fibrillation with rapid ventricular rate (AFib-RVR), which could significantly expand the addressable market. NMPA approval in China was also granted in September 2026.
Analyst consensus is Strong Buy (8 Buy, 3 Strong Buy, 2 Hold) with a mean price target of $5.57, implying massive upside from the current $0.52 price, though targets were set before the recent decline.
▼ Bear Case4
CARDAMYST faces competition from low-cost generic drugs (adenosine, verapamil, diltiazem) used in emergency settings for PSVT, which may limit pricing power and adoption. A Seeking Alpha analysis from August 2026 characterized Q2 revenue of just $559K on over 1,200 scripts as reflecting heavy discounting and minimal payer coverage.
The stock has collapsed from ~$2.95 before FDA approval in December 2025 to $0.52 today, a decline of over 80%, suggesting the market sees limited commercial potential. The company is cutting operating expenses by ~30% to preserve cash.
Institutional holders like Jane Street Group and Simplex Trading nearly exited their positions in Q3 2026, trimming by 77% and 99.3% respectively.
The PSVT indication is a relatively niche market, and the drug's differentiation from existing generic options is questioned by some analysts.

Upcoming Catalysts

  • Phase 3 ReVeRA-301 topline readout for AFib-RVR (no specific date announced)
  • Quarterly prescription and revenue growth updates as commercial launch matures
  • Potential label expansion or additional real-world evidence from the RESET-PSVT registry

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Milestone Pharmaceuticals Inc. 8-K MIST ·Originating report

Sources · 9

Hover a chip for the title
1 markets.businessinsider.com2 seekingalpha.com3 grafa.com4 medpagetoday.com5 medicalnewstoday.com6 seekingalpha.com7 morningstar.com8 tmcnet.com9 seekingalpha.com